Abstract
The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer.
We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2-neu overexpression. Its combination with chemotherapy agents achieves a synergic activity.
Similar content being viewed by others
References
Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neuoverexpressing metastatic breast cancer. Am J Ther. 2005;12(3):243–53.
De Laurentiis M, Cancello G, Zinno L, et al. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Ann Oncol. 2005;16 Suppl 4:S7–13.
Luftner D, Pollmann D, Schildhauer S, et al. Perspectives of immunotherapy in metastatic breast cancer. Anticancer Res. 2005;25(6C):4599–604.
Rossi A, Colantuoni G, Cantore N, et al. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. Anticancer Res. 2004;24(1):317–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Escalante, S.M., Lescure, Á.R., Sanz, V.P. et al. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol 8, 761–763 (2006). https://doi.org/10.1007/s12094-006-0125-6
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12094-006-0125-6